Exceptional Response to Pembrolizumab for Treatment of Metastatic Chemorefractory Endometrial Carcinoma in a Patient with Lynch Syndrome: A Case Report

Advanced endometrial cancer is associated with poor outcomes and few treatment options exist. Recently, the US Federal Drug Administration approved pembrolizumab for the treatment of endometrial cancers that are deficient in mismatch repair and have high microsatellite instability (MSI). Lynch syndr...

Descripción completa

Detalles Bibliográficos
Autores principales: Batman, Samantha, Rauh-Hain, J. Alejandro, Grinsfelder, Michaela Onstad, Harrison, Ross, Avila, Monica, Cun, Han, How, Jeffrey Andrew, Tandon, Nidhi, Wang, Xiaohong, Hinchcliff, Emily, Jazaeri, Amir Anthony, Schmeler, Kathleen M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: S. Karger AG 2023
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10134052/
https://www.ncbi.nlm.nih.gov/pubmed/37123608
http://dx.doi.org/10.1159/000530154

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10134052/
https://www.ncbi.nlm.nih.gov/pubmed/37123608
http://dx.doi.org/10.1159/000530154

Ejemplares similares